{"id":605,"date":"2018-08-08T15:51:23","date_gmt":"2018-08-08T07:51:23","guid":{"rendered":"https:\/\/www.smartnucl.com\/en\/?post_type=news&p=605"},"modified":"2022-06-30T15:52:01","modified_gmt":"2022-06-30T07:52:01","slug":"innovative-radiopharmaceutical-company-smartnuclide-closes-series-pre-a-financing","status":"publish","type":"news","link":"https:\/\/www.smartnucl.com\/en\/archives\/news\/innovative-radiopharmaceutical-company-smartnuclide-closes-series-pre-a-financing","title":{"rendered":"Innovative Radiopharmaceutical Company SmartNuclide Closes Series Pre-A Financing"},"content":{"rendered":"

SUZHOU INDUSTRIAL PARK, March 8, 2018 \u2013 Suzhou SmartNuclide Biopharmaceutical Co., Ltd. (SmartNuclide), a biopharmaceutical company focused on discovering and developing innovative radiopharmaceuticals, today announced that the company secured its Series Pre-A investment round led by Beijing-based Waston Capital, joined by Zhuhai-based Longmen Capital and Suzhou-based Kongton Capital. The proceeds will allow SmartNuclide to run a phase 1\/2 trial with its first clinical program, rhTSH, which is expected to received its IND clearance very soon, as well as further pre-clinical testing for its first radiotracer for whole-body PD-L1 expression imaging.<\/p>\n","protected":false},"excerpt":{"rendered":"

SUZHOU INDUSTRIAL PARK, March 8, 2018 \u2013 Suzhou SmartNuc […]<\/p>\n","protected":false},"featured_media":0,"menu_order":0,"template":"","categories":[19],"_links":{"self":[{"href":"https:\/\/www.smartnucl.com\/en\/wp-json\/wp\/v2\/news\/605"}],"collection":[{"href":"https:\/\/www.smartnucl.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.smartnucl.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/www.smartnucl.com\/en\/wp-json\/wp\/v2\/media?parent=605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.smartnucl.com\/en\/wp-json\/wp\/v2\/categories?post=605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}